Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Vincera Pharma Inc (VINC)

Vincera Pharma Inc (VINC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,969
  • Shares Outstanding, K 33,651
  • Annual Sales, $ 0 K
  • Annual Income, $ -40,160 K
  • EBIT $ -28 M
  • EBITDA $ -28 M
  • 60-Month Beta 1.48
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.67
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.79
  • Most Recent Earnings $-0.17 on 11/12/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.13
  • Number of Estimates 1
  • High Estimate -0.13
  • Low Estimate -0.13
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +43.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1800 +15.06%
on 12/20/24
0.2966 -30.18%
on 12/02/24
-0.0685 (-24.85%)
since 11/20/24
3-Month
0.1800 +15.06%
on 12/20/24
0.7837 -73.57%
on 09/24/24
-0.5233 (-71.65%)
since 09/20/24
52-Week
0.1800 +15.06%
on 12/20/24
9.3722 -97.79%
on 03/11/24
-0.4409 (-68.04%)
since 12/20/23

Most Recent Stories

More News
Vincerx Pharma Announces Cost-Cutting Measures and Exploration of Strategic Alternatives to Advance VIP943 Clinical Development

Vincerx Pharma plans cost-controls and strategic alternatives to advance VIP943, a promising cancer treatment currently in Phase 1 study.Quiver AI SummaryVincerx Pharma, Inc. announced plans to implement...

VINC : 0.2071 (+0.15%)
Vincerx Pharma Stock Gets Retail Followers Buzzing With Big Layoff Plans To Sustain Cancer Drug Trials

The company's plans include a 55% reduction in force and exploring strategic alternatives such as out-licensing, mergers, or asset sales.

VINC : 0.2071 (+0.15%)
Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943

VINC : 0.2071 (+0.15%)
Vincerx Pharma Reports Third Quarter 2024 Financial Results

VINC : 0.2071 (+0.15%)
Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates

VINC : 0.2071 (+0.15%)
Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress

Preclinical data demonstrate VIP152 as the most selective CDK9 inhibitor compared with other CDK9 inhibitors, with the most robust MYC mRNA downregulation ...

VINC : 0.2071 (+0.15%)
Vincerx Pharma Provides Key Strategic Update

Prioritizing Phase 1b VIP152 studies to focus on double-hit DLBCL and CLL Continuing to advance next-generation modular bioconjugation platform; IND...

VINC : 0.2071 (+0.15%)
Vincerx Pharma Reports First Quarter 2022 Financial Results and Provides a Corporate Update

Company to present poster on VIP152 at upcoming European Hematology Association Annual Meeting Presented preliminary findings on VIP152 in gynecologic...

VINC : 0.2071 (+0.15%)
Vincerx Pharma Presents Preclinical and Preliminary Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Gynecologic Malignancies at the American Association for Cancer Research (AACR) Annual Meeting 2022

VIP152 demonstrates antitumor responses in preclinical models of gynecologic malignancies Preliminary monotherapy clinical results presented for...

VINC : 0.2071 (+0.15%)
Vincerx Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

Dosed first patient in VIP152 and pembrolizumab combination arm of study VNC-152-101 Preliminary findings in gynecologic malignancies will be presented as...

VINC : 0.2071 (+0.15%)

Business Summary

Vincerx Pharma Inc. is a biopharmaceutical company. It focuses on unmet medical needs of patients with cancer through paradigm-shifting therapeutics. Vincerx Pharma Inc. is based in PALO ALTO, Calif.

See More

Key Turning Points

3rd Resistance Point 0.2564
2nd Resistance Point 0.2357
1st Resistance Point 0.2214
Last Price 0.2071
1st Support Level 0.1864
2nd Support Level 0.1657
3rd Support Level 0.1514

See More

52-Week High 9.3722
Fibonacci 61.8% 5.8608
Fibonacci 50% 4.7761
Fibonacci 38.2% 3.6914
Last Price 0.2071
52-Week Low 0.1800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar